We are excited to announce the release of our latest whitepaper, “AI Co-Scientists for Drug Discovery.” This in-depth report explores how next-generation AI agents are transforming preclinical drug R&D—accelerating hypothesis generation, experimental design, and data-driven decision-making. The whitepaper provides a clear overview of the current landscape, practical use cases, and the challenges and opportunities of integrating AI co-scientists into biomedical research.

Discover how Trail Biomed’s approach combines domain-aware AI with rigorous scientific workflows to ensure transparency, reproducibility, and trust in drug development.

Read the full whitepaper here

Gergely Szabó joins Trail as head of Software Engineering, Welcome to the growing team

Leah Soriaga and Amalio Telenti publish today work performed at Vir Biotechnology on the human host genetic landscape of The genetic underpinnings of respiratory viral infection. This is a landmark study of the network of genes supporting infection of 9 human respiratory viruses: influenza, parainfluenza virus, rhinovirus, RSV, common human coronavirus, MERS and SARS-CoV-2. Link: https://www.pnas.org/doi/epub/10.1073/pnas.2414202122

Leah Soriaga joins Trail as head of bioinformatics, and Zita Rovó joins as head of product. Welcome to the growing team!

Trail Biomed is awarded a grant of over $2.65million from the Gates Foundation. Trail Biomed, a Swiss company founded by AmalioTelenti, aims at advancing global health through innovative therapeutics. This funding will support the development of a working framework for data interoperability and validation, integrating wet bench data generation with AI tools to create novel, cost-effective small molecule therapies to improve public health.This initiative represents a significant step toward addressing critical gaps in data integration and fostering rapid testing and validation of drug leads. For more information, visit trail biomed.